Cargando…

Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience

BACKGROUND: Recent observations suggest a lack of humoral response after SARS-CoV-2 vaccination in multiple sclerosis (MS) patients treated with fingolimod or ocrelizumab OBJECTIVES: To assess serological response to SARS-CoV-2 vaccination in MS patients receiving these disease-modifying treatments...

Descripción completa

Detalles Bibliográficos
Autores principales:	S., Guerrieri, S., Lazzarin, C., Zanetta, A., Nozzolillo, M., Filippi, L., Moiola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241206/ https://www.ncbi.nlm.nih.gov/pubmed/34189719 http://dx.doi.org/10.1007/s00415-021-10663-x

Ejemplares similares

Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod
por: Capuano, Rocco, et al.
Publicado: (2022)

COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience
por: Preziosa, Paolo, et al.
Publicado: (2020)

Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study
por: Bigaut, Kévin, et al.
Publicado: (2022)

Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
por: Palomares Cabeza, Virginia, et al.
Publicado: (2022)

Atrioventricular block after fingolimod resumption: a consequence of sphingosine-1-phosphate axis alteration due to COVID-19?
por: Orrico, Mario, et al.
Publicado: (2021)

Serology results after COVID vaccine in multiple sclerosis patients treated with fingolimod
por: Ciccone, A., et al.
Publicado: (2023)

Modifiable risk factors of COVID-19 in patients with multiple sclerosis: a single-centre case–control study
por: Montini, Federico, et al.
Publicado: (2023)

Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)
por: Chisari, Clara G., et al.
Publicado: (2023)

Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab
por: Katz, J.D., et al.
Publicado: (2022)

COVID-19 in ocrelizumab-treated people with multiple sclerosis
por: Hughes, Richard, et al.
Publicado: (2021)

Real-world experience of ocrelizumab in multiple sclerosis in an Arab population
por: Garcia-Cañibano, Beatriz, et al.
Publicado: (2021)

Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod
por: Mallucci, Giulia, et al.
Publicado: (2020)

Severe rebound after cessation of fingolimod treated with ocrelizumab with coincidental transient aggravation: report of two cases
por: Schmidt, Stephan, et al.
Publicado: (2019)

Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing–remitting multiple sclerosis patients: a monocentric longitudinal observational study
por: Zanetta, Chiara, et al.
Publicado: (2023)

Myeloid cells as target of fingolimod action in multiple sclerosis
por: Di Dario, Marco, et al.
Publicado: (2015)

Correction to: Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing–remitting multiple sclerosis patients: a monocentric longitudinal observational study
por: Zanetta, Chiara, et al.
Publicado: (2023)

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

Preliminary evidence of blunted humoral response to SARS-Cov-2 (MRNA) vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis
por: Daniels, K., et al.
Publicado: (2020)

Ocrelizumab in Multiple Sclerosis: A Real-World Study From Spain
por: Sempere, Angel P., et al.
Publicado: (2021)

Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population
por: Fernandez‐Diaz, Eva, et al.
Publicado: (2020)

Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America
por: ROJAS, Juan Ignacio, et al.
Publicado: (2021)

Real‐world evaluation of ocrelizumab in multiple sclerosis: A systematic review
por: Montalban, Xavier, et al.
Publicado: (2023)

Ocrelizumab: A Review in Multiple Sclerosis
por: Lamb, Yvette N.
Publicado: (2022)

Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
por: Capuano, Rocco, et al.
Publicado: (2022)

Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis
por: Gibson, Elena G, et al.
Publicado: (2021)

Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab
por: Habek, Mario, et al.
Publicado: (2022)

Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis
por: Pompsch, Mosche, et al.
Publicado: (2021)

Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients
por: Georgieva, Zoya G, et al.
Publicado: (2021)

Immune monitoring of SARS-CoV-2-specific T cell and B cell responses in patients with multiple sclerosis treated with ocrelizumab
por: Groß-Albenhausen, Elina, et al.
Publicado: (2023)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
por: Cellerino, Maria, et al.
Publicado: (2021)

Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report
por: Lucchini, Matteo, et al.
Publicado: (2020)

Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab
por: Suwanwongse, Kulachanya, et al.
Publicado: (2020)

Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab
por: Pedotti, Rosetta, et al.
Publicado: (2021)

Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection
por: Landi, Doriana, et al.
Publicado: (2022)

Disseminated Histoplasmosis in a Patient With Multiple Sclerosis Treated With Fingolimod
por: Abrahamowicz, Aleksandra A., et al.
Publicado: (2021)

Metabolomic Changes in Patients Affected by Multiple Sclerosis and Treated with Fingolimod
por: Murgia, Federica, et al.
Publicado: (2023)

Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?
por: Tazza, F., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0f57bldgg86vs8sssc5m651lco